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Introduction
The dominantly inherited cryopyrin-associated periodic
syndromes (CAPS) are caused by heterozygous missense
gain-of-function mutations in the NLRP3 (CIAS1) gene
encoding NLRP3 (also known as cryopyrin). Most patients
present at a young age with a variety of clinical symptoms
including fevers, urticaria-like skin rash, arthropathy, and
CNS inflammation. A subset of patients followed at the
National Institute of Health’s autoinflammatory disease
clinic has adult-onset fevers and urticarial rash but con-
ventional genetic testing has been unremarkable for any
mutations in NLRP3. We analyzed one such “mutation-
negative” patient. She is a 63y/o female of Irish ancestry
who developed a gradually worsening stress-induced urti-
carial rash in her 40s. Additional clinical history is remark-
able for severe arthralgia, myalgia, chills, and occasional
conjunctivitis. Initially started on anakinra 100mg/day
in 2003, she had dramatic improvement in symptoms;
however, her anakinra dose has required periodic adjust-
ments since that time to control her symptoms.
Objectives
To identify the cause of disease in a patient who presented
with late-onset CAPS and who was mutation-negative in
NLRP3 based on the conventional Sanger sequencing.
Methods
We performed whole exome sequencing in the DNA
sample extracted from peripheral blood. A total of 192
subclones were randomly selected and subjected to Sanger
sequencing to validate the NLRP3 somatic mutation.
Targeted deep sequencing on NLRP3 will be done using
the DNA from blood and buccal cells.
Results
Our established exome data analysis pipeline failed to
identify any plausible candidate gene in this patient. In
order to increase the sensitivity of variant calling, we used
a different combination of parameters including calling
SNPs/Indels with extreme strand bias, which resulted in a
rapid increase in false positive rate but also raised the pos-
sibility of identifying somatic mosaicism mutations. Based
on this new analytic approach, we identified a possible
mutation p.Tyr570Cys (c.1709A>G) in NLRP3. Exome
data showed that there are 12 reads carrying the mutant
G allele and 64 reads carrying the wild type A allele (15%).
This mutation has been previously reported in a NOMID/
CINCA patient from Australia. The putative mosaic p.
Tyr570Cys mutation was validated by subcloning a 718bp
fragment from the patient’s leukocyte DNA and subse-
quent Sanger sequencing of 192 clones. We found
20 clones carrying the p.Tyr570Cys mutation, which estab-
lished the level of somatic mosaicism at 10.4%. We are
in the process of evaluating this mosaic mutation in other
tissues from this patient.
Conclusion
We report NLRP3 somatic mosaicism in a patient present-
ing with a late onset CAPS. To our knowledge this is the
first time that a NLRP3 mutation has been identified in
patients developing symptoms in adulthood. Other possi-
ble causal genes have been ruled out based on exome
sequencing analysis. Our result contributes significantly to
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